MX2018015960A - Formulacion farmaceutica liquida estable. - Google Patents

Formulacion farmaceutica liquida estable.

Info

Publication number
MX2018015960A
MX2018015960A MX2018015960A MX2018015960A MX2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A MX 2018015960 A MX2018015960 A MX 2018015960A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
liquid pharmaceutical
stable liquid
antibody
preparation according
Prior art date
Application number
MX2018015960A
Other languages
English (en)
Inventor
Young Kim So
Won Lee Joon
Yong Han Won
Jung Kim Su
Seok Oh Jun
Hyeon Hong Su
Kyeong Shin Yeon
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015960(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of MX2018015960A publication Critical patent/MX2018015960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención proporciona una formulación farmacéutica líquida estable que contiene: un anticuerpo o su fragmento de unión a antígeno; un tensioactivo; un azúcar o su derivado; y un tampón. La formulación farmacéutica líquida estable de acuerdo con la presente invención tiene baja viscosidad a la vez que contiene un contenido elevado del anticuerpo, tiene una estabilidad durante el almacenamiento a largo plazo excelente basándose en la estabilidad excelente en condiciones aceleradas y condiciones severas, y se puede administrar por vía subcutánea.
MX2018015960A 2016-06-30 2017-06-28 Formulacion farmaceutica liquida estable. MX2018015960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30
PCT/KR2017/006855 WO2018004260A1 (ko) 2016-06-30 2017-06-28 안정한 액체 약제학적 제제

Publications (1)

Publication Number Publication Date
MX2018015960A true MX2018015960A (es) 2019-03-21

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015960A MX2018015960A (es) 2016-06-30 2017-06-28 Formulacion farmaceutica liquida estable.

Country Status (34)

Country Link
US (1) US11951207B2 (es)
EP (2) EP3479819B1 (es)
JP (2) JP7082070B2 (es)
KR (3) KR20180003452A (es)
CN (1) CN109310628A (es)
AU (2) AU2017287743C1 (es)
BR (1) BR112018076377A2 (es)
CA (1) CA3028238C (es)
CL (1) CL2018003662A1 (es)
CO (1) CO2018013689A2 (es)
CR (1) CR20180599A (es)
CU (1) CU24561B1 (es)
DK (1) DK3479819T3 (es)
DO (1) DOP2018000290A (es)
EA (1) EA201892653A1 (es)
EC (1) ECSP18093651A (es)
FI (1) FI3479819T3 (es)
GE (1) GEP20217249B (es)
IL (1) IL263630B2 (es)
JO (1) JOP20180125B1 (es)
LT (1) LT3479819T (es)
MA (1) MA45562A (es)
MX (1) MX2018015960A (es)
NI (1) NI201800139A (es)
PE (1) PE20190448A1 (es)
PH (1) PH12018502670A1 (es)
PT (1) PT3479819T (es)
RS (1) RS65395B1 (es)
SG (1) SG11201811320YA (es)
TN (1) TN2018000443A1 (es)
TW (1) TWI736643B (es)
UA (1) UA122610C2 (es)
WO (1) WO2018004260A1 (es)
ZA (1) ZA201808476B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2018207367B2 (en) 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060183A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 트라스투주맙 항체 안정화 액체 제제
EP3865154A4 (en) * 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
EP3927729A4 (en) 2019-02-18 2023-10-11 Eli Lilly and Company THERAPEUTIC ANTIBODY FORMULATION
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
JP2022525556A (ja) * 2019-03-18 2022-05-17 アルヴォテック エイチエフ Ｔｎｆ－アルファ抗体の高濃度水性製剤
CN110095615A (zh) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
KR20220152540A (ko) * 2020-03-13 2022-11-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
AU2022348349A1 (en) * 2021-09-16 2024-05-02 Aprogen Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
TW202333788A (zh) * 2021-12-28 2023-09-01 大陸商江蘇先聲藥業有限公司 一種抗ｔｎｆｒ２抗體藥物組合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69319753T2 (de) 1992-11-19 1999-04-15 Galli Rosaria & C Automatische injektionsvorrichtung für vorgefüllte spritzen
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EA033387B1 (ru) * 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
AU2013221635B2 (en) * 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
AU2013255413C1 (en) 2012-03-07 2016-03-24 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
CN104854133B (zh) * 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
EP2911693A4 (en) * 2012-10-25 2016-04-27 Medimmune Llc STABLE, LOW-VISIC ANTIBODY FORMULATION
US20140161790A1 (en) * 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
BR112015017619A2 (pt) 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
CN104666242B (zh) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU01248A (es) * 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
ES2600488T3 (es) * 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016103093A1 (en) 2014-12-23 2016-06-30 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
BR112017016636A2 (pt) * 2015-02-13 2018-04-03 Sanofi Sa formulação líquida estável para anticorpos monoclonais
AR118191A1 (es) 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Also Published As

Publication number Publication date
IL263630A (en) 2019-01-31
EP4338752A3 (en) 2024-04-03
EP3479819A4 (en) 2020-02-26
JOP20180125B1 (ar) 2022-09-15
MA45562A (fr) 2019-05-08
AU2020201249A1 (en) 2020-03-12
EP4338752A2 (en) 2024-03-20
ZA201808476B (en) 2020-08-26
IL263630B2 (en) 2023-06-01
CR20180599A (es) 2019-04-09
ECSP18093651A (es) 2019-01-31
CN109310628A (zh) 2019-02-05
CU24561B1 (es) 2022-01-13
KR20180097471A (ko) 2018-08-31
CL2018003662A1 (es) 2019-03-15
CO2018013689A2 (es) 2019-01-18
AU2017287743B2 (en) 2020-01-30
KR20180003452A (ko) 2018-01-09
AU2017287743C1 (en) 2020-10-01
FI3479819T3 (fi) 2024-04-17
PT3479819T (pt) 2024-04-15
TWI736643B (zh) 2021-08-21
PH12018502670A1 (en) 2019-10-07
KR102397713B1 (ko) 2022-05-13
BR112018076377A2 (pt) 2019-03-26
JP7405324B2 (ja) 2023-12-26
RS65395B1 (sr) 2024-04-30
CA3028238C (en) 2024-01-02
US11951207B2 (en) 2024-04-09
EA201892653A1 (ru) 2019-05-31
CU20180154A7 (es) 2019-08-06
KR102229274B1 (ko) 2021-03-18
JOP20180125A1 (ar) 2019-01-30
EP3479819A1 (en) 2019-05-08
KR20210042052A (ko) 2021-04-16
GEP20217249B (en) 2021-04-26
WO2018004260A1 (ko) 2018-01-04
EP3479819B1 (en) 2024-01-24
LT3479819T (lt) 2024-04-25
AU2020201249B2 (en) 2021-07-15
TW201806617A (zh) 2018-03-01
UA122610C2 (uk) 2020-12-10
AU2017287743A1 (en) 2018-11-22
DK3479819T3 (da) 2024-04-15
PE20190448A1 (es) 2019-03-29
TN2018000443A1 (en) 2020-06-15
JP2022122941A (ja) 2022-08-23
DOP2018000290A (es) 2019-02-15
CA3028238A1 (en) 2018-01-04
NI201800139A (es) 2019-03-25
NZ748101A (en) 2020-11-27
JP2019525902A (ja) 2019-09-12
US20210000743A1 (en) 2021-01-07
JP7082070B2 (ja) 2022-06-07
SG11201811320YA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
PH12018502670A1 (en) Stable liquid pharmaceutical preparation
EP4272763A3 (en) Liquid protein formulations containing organophosphates
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
MX370207B (es) Composiciones estabilizadas de anticuerpos.
MX2019009176A (es) Formulaciones de etanercept estabilizadas con iones metalicos.
MY184266A (en) Anti-cgrp antibody formulation
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MX359999B (es) Vacunas de virus bovino liquidas estables.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
AR098168A1 (es) Formulación estable de insulina glulisina
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
IN2014MU01248A (es)
EA201691132A1 (ru) Инъекционное средство и способ образования депо
PH12017500661A1 (en) Reduced foaming vaccine compositions
MY194758A (en) Stable liquid pharmaceutical formulation
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
MX2020010928A (es) Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
TH1701002015A (th) องค์ประกอบวัคซีนที่การเกิดฟองลดลง